PXS 0.00% 8.5¢ pharmaxis ltd

Ann: Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. lightbulb Created with Sketch. 851
    • Release Date: 11/10/18 08:27
    • Summary: Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor
    • Price Sensitive: Yes
    • Download Document    Not available as of the moment.
 
watchlist Created with Sketch. Add PXS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.